Insulet Corp

Common Name
Insulet
Country
United States
Sector
Healthcare
Industry
Medical Devices
Employees
3,900
Ticker
PODD
Exchange
NASDAQ/NGS
Description
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innov...

Insulet's Financial Statements Preview

Below are the financial statements of Insulet, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of USD
2024
2023
2022
Revenue
1,483.8a
1,223.4a
1,055.4a
Revenue from related party
587.8a
473.7a
249.9a
Total revenue
2,071.6a
1,697.1a
1,305.3a
Cost of revenue
-625.9a
-537.2a
-499.7a
Gross profit
1,445.7a
1,159.9a
805.6a
Research and development expenses
-219.6a
-205a
-180.2a
Selling, general and administrative expenses
-917.2a
-734.9a
-587.8a
Operating income
308.9a
220a
37.6a
Interest expense, net of portion capitalized
-42.7a
-36.2a
-36a
Interest income
39.5a
28.6a
9.3a
Other (expense) income, net
-5.5a
2.2a
-1.1a
Income before income taxes
300.2a
214.6a
9.8a
Income tax benefit (expense)
-118.1a
-8.3a
-5.2a
Net income
418.3a
206.3a
4.6a
Download Data

Verified Sources Behind Insulet’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Insulet’s data sources below and access millions more through our Disclosure Search.

a. Insulet's 10-K 2024
a. Insulet's 10-K 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?